Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
10/02/2026
The Thai stock market rose by as much as 0.8% to 1412.32 points, reaching its highest level since December 17, 2024.
Latest
5 m ago
The yield on Japanese 20-year government bonds fell by 4.0 basis points to 3.125%.
6 m ago
Changchuan Technology: The company has started the construction of the second phase project of Changchuan Neijiang Base in the second half of 2025. Its main function is to serve as a production base in the southwestern region of the country.
10 m ago
According to each AI, Guojin Securities issued a research report on February 10, giving a "buy" rating to Tech-Bio (688278.SH) with a target price of 92.74 yuan. The main reasons for the rating include: 1) PEG leading enterprise in long-acting drugs, with potential for performance growth after 26 years; 2) Long-acting interferon: significant advantages in efficacy and maintenance rates, with a solid foundation; 3) Long-acting growth hormone: wide space for formulation upgrades, expanding second growth point with differentiated characteristics. (Daily Economic News)
10 m ago
According to AI Express, Huayuan Securities released a research report on February 10th, giving Huatai Medical (688617.SH) a "buy" rating. The main reasons for the rating include: 1) Deep layout in cardiovascular intervention, multidimensional product development; 2) Technological changes + import substitution drive industry growth, barrier created by combination of environment + line products; 3) Centralized procurement strengthens the foundation of coronary artery and vascular intervention, and the potential for capacity expansion is expected to be further released. (Daily Economic News)
13 m ago
The Taiwan Work Conference in 2026 was held in Beijing. Wang Huning attended and delivered a speech.
See all latest